Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. Cardio was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in treatment of cardiovascular disease.
Company profile
Ticker
CDIO
Exchange
Employees
Location
Fiscal year end
Industry (SIC)
Former names
Mana Capital Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Cardio Diagnostics, Inc. ...
IRS number
870925574
CDIO stock data
Latest filings (excl ownership)
8-K
COMPANY UPDATE Revolutionizing Cardiovascular Medicine With Epigenetics and AI MARCH 2024
2 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
D
Exempt offering of security
6 Feb 24
8-K
Unregistered Sales of Equity Securities
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
424B5
Prospectus supplement for primary offering
1 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
UPLOAD
Letter from SEC
30 Jan 24
S-3
Shelf registration
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.63 mm | 3.63 mm | 3.63 mm | 3.63 mm | 3.63 mm | 3.63 mm |
Cash burn (monthly) | 471.56 k | 444.53 k | 644.13 k | 836.37 k | 644.13 k | 831.87 k |
Cash used (since last report) | 3.14 mm | 2.96 mm | 4.29 mm | 5.57 mm | 4.29 mm | 5.54 mm |
Cash remaining | 490.73 k | 670.65 k | -657.96 k | -1.94 mm | -657.96 k | -1.91 mm |
Runway (months of cash) | 1.0 | 1.5 | -1.0 | -2.3 | -1.0 | -2.3 |
Institutional ownership, Q2 2023
15.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 9 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 705.36 mm |
Total shares | 3.23 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Robert Philibert | 1.59 mm | $2.00 mm |
EHP Funds | 228.95 k | $43.16 mm |
Walleye Capital | 223.39 k | $42.11 mm |
Saba Capital Management | 199.84 k | $37.67 mm |
Walleye Trading | 125.79 k | $23.71 mm |
Prelude Capital Management | 110.00 k | $130.90 mm |
Clear Street | 82.94 k | $16.00 k |
Context Capital Management | 81.50 k | $15.00 k |
Geode Capital Management | 75.48 k | $89.82 mm |
D. E. Shaw & Co. | 74.82 k | $9.50 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Oded Levy | Common Stock | Option exercise | Acquire M | No | No | 1.42 | 8,803 | 12.50 k | 71,596 |
31 Mar 24 | Oded Levy | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | - | 12.50 k | - |
31 Mar 24 | James Intrater | Common Stock | Option exercise | Acquire M | No | No | 1.42 | 8,803 | 12.50 k | 71,596 |
31 Mar 24 | James Intrater | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | - | 12.50 k | - |
31 Mar 24 | Stanley K. Lau | Common Stock | Option exercise | Acquire M | No | No | 1.42 | 8,803 | 12.50 k | 100,325 |
31 Mar 24 | Stanley K. Lau | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | - | 12.50 k | - |
31 Mar 24 | Paul Frederick Burton | Common Stock | Option exercise | Acquire M | No | No | 1.42 | 8,803 | 12.50 k | 8,803 |
31 Mar 24 | Paul Frederick Burton | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | - | 12.50 k | - |
31 Jan 24 | Stanley K. Lau | Common Stock | Option exercise | Acquire M | No | No | 2.18 | 917 | 2.00 k | 91,522 |
31 Jan 24 | Stanley K. Lau | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | - | 2.00 k | 0 |
News
12 Health Care Stocks Moving In Monday's After-Market Session
15 Apr 24
Exponential Health Earlier Announced It Partnered With Cardio Diagnostics For Cardiovascular Disease Prevention In Michigan
9 Apr 24
BlackRock Bolsters Wealth Management Arsenal With SpiderRock Advisors Acquisition, Expanding SMA Solutions
8 Mar 24
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
5 Mar 24
Cardio Diagnostics Holdings, Inc. Announces U.S. Patent Application No. 17,857,723 For Compositions And Methods For Detecting Predisposition To Cardiovascular Disease
5 Mar 24
Press releases
Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests
12 Apr 24
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan
9 Apr 24
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
4 Apr 24
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology's 73rd Annual Scientific Session
14 Mar 24
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
5 Mar 24